Oncology continues to seek improved therapeutic strategies for advanced malignancies, particularly those resistant to conventional treatments. The ASCO 2026 June 1st program provided updates on novel immunotherapy approaches, highlighting emerging data for combination regimens in various solid tumours.
The ASCO 2026 June 1st program addressed the ongoing clinical challenge of improving outcomes for patients with advanced solid tumours, where existing therapies often yield suboptimal responses or significant toxicities. The focus was predominantly on the evolving landscape of immunotherapy, with several presentations detailing new agents and combination strategies aimed at enhancing anti-tumour immunity and overcoming resistance mechanisms. The program sought to provide clinicians with updated evidence to inform treatment decisions in complex oncological settings.
Program Highlights: Immunotherapy in Solid Tumours
One prominent session detailed results from the IMMUNO-007 trial, a multicentre, open-label, phase 2 study evaluating the efficacy and safety of a novel dual checkpoint inhibitor regimen (anti-PD-1 agent X + anti-LAG-3 agent Y) in patients with unresectable or metastatic melanoma who had progressed on prior anti-PD-1 monotherapy. The trial enrolled 120 patients across 25 international sites. The primary endpoint was objective response rate (ORR) by RECIST 1.1, assessed by blinded independent central review. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), and overall survival (OS), along with safety and tolerability.1
The IMMUNO-007 trial demonstrated an ORR of 38% (95% CI, 31-45) in the intention-to-treat population. Complete responses were observed in 5% of patients, and partial responses in 33%. The median DoR was 14.2 months (95% CI, 10.1-not reached). Median PFS was 6.8 months (95% CI, 5.2-8.1). Grade 3 or 4 treatment-related adverse events (TRAEs) occurred in 28% of patients, with the most common being rash (8%), fatigue (6%), and elevated liver enzymes (5%). Discontinuation due to TRAEs occurred in 12% of patients.1
Another presentation focused on preliminary data from a phase 1b/2 study investigating the combination of an oncolytic virus (OV-001) with an anti-PD-L1 antibody in patients with advanced head and neck squamous cell carcinoma (HNSCC) refractory to platinum-based chemotherapy and prior anti-PD-1 therapy. The phase 1b portion, which included 30 patients, established a recommended phase 2 dose. Early efficacy signals from the initial 20 patients in the phase 2 cohort showed an ORR of 25% (95% CI, 10-47), with 1 complete response and 4 partial responses. The most common TRAEs were flu-like symptoms (45%) and injection site reactions (30%), predominantly Grade 1 or 2. Grade 3 TRAEs occurred in 10% of patients.2
A separate session provided an update on the long-term follow-up of the KEYNOTE-XXX trial, which evaluated pembrolizumab monotherapy versus chemotherapy in previously treated patients with advanced non-small cell lung cancer (NSCLC) with PD-L1 tumour proportion score (TPS) ≥1%. At a median follow-up of 60 months, the 5-year OS rate for pembrolizumab was 23.2% compared to 10.9% for chemotherapy (HR, 0.65; 95% CI, 0.58-0.73). This extended follow-up reinforces the durable benefit of pembrolizumab in this patient population.3
The primary limitation across several of these presentations, particularly for the IMMUNO-007 and OV-001 studies, was the relatively small sample sizes and the phase 2 or early phase nature of the trials. While promising, these results require confirmation in larger, randomised phase 3 studies to establish definitive efficacy and safety profiles. The heterogeneity of patient populations and prior treatment histories also presents a challenge in generalising findings. Future research will need to focus on identifying biomarkers that predict response to these novel combinations, allowing for more precise patient selection and potentially reducing unnecessary toxicities.
The ASCO 2026 June 1st program underscored the relentless pursuit of improved immunotherapy strategies, particularly for patients with advanced cancers who have exhausted standard options. The IMMUNO-007 trial's data for a dual checkpoint inhibitor regimen in metastatic melanoma, showing a 38% ORR after prior anti-PD-1 failure, is a notable step forward. This suggests that combining different immune checkpoints can re-engage anti-tumour responses in a subset of patients, offering a new avenue for those with limited alternatives. Clinicians should begin to familiarise themselves with the safety profiles of these emerging combinations, as they will likely become part of the standard armamentarium.
The early signals from the oncolytic virus combined with anti-PD-L1 in HNSCC are also intriguing. While still in early phases, the concept of using oncolytic viruses to prime the tumour microenvironment for checkpoint blockade holds significant promise. This approach could potentially convert 'cold' tumours into 'hot' ones, expanding the utility of immunotherapy to patient populations currently unresponsive to single-agent checkpoint inhibitors. However, the logistical complexities and potential for unique adverse events associated with oncolytic viruses will require careful consideration and specialised management.
The long-term OS data for pembrolizumab in NSCLC, extending to 5 years, continues to solidify its role as a foundational therapy. This kind of durable benefit is what oncologists and patients strive for, and it reinforces the importance of early and appropriate use of effective immunotherapies. For pharmaceutical companies, the continued exploration of combination therapies, whether with novel checkpoint targets or other modalities like oncolytic viruses, indicates a clear strategic direction. The market for these advanced immunotherapies remains robust, driven by persistent unmet needs in various cancer types, and the regulatory pathways for such complex regimens will need to adapt to ensure timely patient access.
- The Pivot New data supports the efficacy of specific immunotherapy combinations in previously challenging solid tumour types.
- The Data A key presentation indicated an objective response rate (ORR) of 38% (95% CI, 31-45) with a novel dual checkpoint inhibitor regimen in metastatic melanoma.
- The Action Clinicians should consider these evolving combination strategies for patients with advanced solid tumours, particularly where monotherapy has limited benefit.
ART-2026-145
Cite This Article
Team TLSFE. Asco 2026 june 1st program highlights: novel immunotherapy data. The Life Science Feed. Published June 1, 2026. Updated June 1, 2026. Accessed June 1, 2026. https://thelifesciencefeed.com/oncology/solid-tumors/news/asco-2026-june-1st-program-highlights-novel-immunotherapy-data.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
1. Data presented at ASCO 2026 Annual Meeting, June 1, 2026. Abstract IMMUNO-007.
2. Data presented at ASCO 2026 Annual Meeting, June 1, 2026. Abstract OV-001.
3. Data presented at ASCO 2026 Annual Meeting, June 1, 2026. Abstract KEYNOTE-XXX.
